Avoid common mistakes on your manuscript.
Correction to : Annals of Hematology
The first name of authors were erroneously presented (correct Volker Schmidt instead of Schmidt Volker; correct Christian Späth instead of Späth Wolfgang). In Fig. 2B, the n value of de novo AML should be 389 instead of 369. In Fig. 2D, the n value of ≤ 6 months should be 271 instead of 86 and the n value of > 18 months should be 86 instead of 271.
The original article has been corrected.
(Relapsed patients). A Overall survival (OS) of patients with AML after frst relapse according to age. B Overall survival (OS) of patients with AML after frst relapse according to de novo, secondary, and therapy-related AML. C Overall survival (OS) of patients with AML after frst relapse according to favorable, intermediate, and unfavorable cytogenetics. D Overall survival (OS) of patients with AML after frst relapse according to time interval CR1 and relapse in months
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heinicke, T., Krahl, R., Kahl, C. et al. Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol 100, 2877–2878 (2021). https://doi.org/10.1007/s00277-021-04638-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04638-1